Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Total Valuation
ArriVent BioPharma, Inc. has a market cap or net worth of $1.02B. The enterprise value is $526.49M.
Market Cap$1.02B
Enterprise Value$526.49M
Share Statistics
ArriVent BioPharma, Inc. has 41,281,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,281,360
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ArriVent BioPharma, Inc.’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -36.55%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-36.55%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee0.00
Profits Per Employee-1.55M
Employee Count52
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ArriVent BioPharma, Inc. is ―. ArriVent BioPharma, Inc.’s PEG ratio is -0.58.
PE Ratio―
PS Ratio0.00
PB Ratio3.25
Price to Fair Value3.25
Price to FCF-11.94
Price to Operating Cash Flow-5.72
PEG Ratio-0.58
Income Statement
In the last 12 months, ArriVent BioPharma, Inc. had revenue of 0.00 and earned -80.49M in profits. Earnings per share was -2.56.
Revenue0.00
Gross Profit0.00
Operating Income-94.31M
Pretax Income-80.49M
Net Income-80.49M
EBITDA-80.49M
Earnings Per Share (EPS)-2.56
Cash Flow
In the last 12 months, operating cash flow was -146.08M and capital expenditures 0.00, giving a free cash flow of -146.08M billion.
Operating Cash Flow-146.08M
Free Cash Flow-146.08M
Free Cash Flow per Share-3.54
Dividends & Yields
ArriVent BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change-5.91%
50-Day Moving Average20.41
200-Day Moving Average20.34
Relative Strength Index (RSI)64.41
Average Volume (3m)344.18K
Important Dates
ArriVent BioPharma, Inc. upcoming earnings date is Mar 26, 2026, After Close (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
ArriVent BioPharma, Inc. as a current ratio of 13.14, with Debt / Equity ratio of 0.04%
Current Ratio13.14
Quick Ratio13.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ArriVent BioPharma, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ArriVent BioPharma, Inc. EV to EBITDA ratio is -9.49, with an EV/FCF ratio of -10.88.
EV to Sales0.00
EV to EBITDA-9.49
EV to Free Cash Flow-10.88
EV to Operating Cash Flow-10.88
Balance Sheet
ArriVent BioPharma, Inc. has $300.27M in cash and marketable securities with $56.00K in debt, giving a net cash position of $300.21M billion.
Cash & Marketable Securities$300.27M
Total Debt$56.00K
Net Cash$300.21M
Net Cash Per Share$7.27
Tangible Book Value Per Share$8.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ArriVent BioPharma, Inc. is $41.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.57
Price Target Upside70.72% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-75.31%